We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Identifies Genes Linked to Autoimmune Kidney Disease

By LabMedica International staff writers
Posted on 14 Mar 2017
A pair of genes linked to serum levels of the defective immunoglobulin galactose-deficient IgA1 has been identified during a genome-wide association study (GWAS) and may serve as biomarkers to help diagnose the autoimmune kidney disease IgA nephropathy (IgAN), or Berger's disease.

IgAN occurs when the mutated form of the antibody immunoglobulin A (IgA) causes inflammation of the glomeruli, which impedes the kidneys' ability to filter waste from the blood. More...
The primary molecular defect in individuals with IgAN is abnormal O-glycosylation of IgA antibodies. O-glycosylation is a common type of post-translational modification of proteins; specific abnormalities in the mechanism of O-glycosylation have been implicated in cancer, inflammatory, and blood diseases. However, the molecular basis of abnormal O-glycosylation in these complex disorders is not known.

Investigators at the Columbia University Medical Center used a simple lectin-based ELISA assay, based on a GalNAc-specific lectin from Helix aspersa (HAA), to determine the levels of circulating Gd-IgA1 in sera from 2,633 people of European and East Asian ancestry, populations with high rates of the disease. Results obtained with this assay, revealed that serum levels of Gd-IgA1 represented a normally distributed quantitative trait in healthy populations, but up to two thirds of IgAN patients had levels above the 95th percentile for healthy controls.

The screen identified two genome-wide significant loci in the C1GALT1 and C1GALT1C1 genes. These genes encode molecular partners essential for enzymatic O-glycosylation of IgA1. These two loci explained approximately 7% of variability in circulating Gd-IgA1 in Europeans, but only 2% in East Asians. Moreover, many healthy family members exhibited very high Gd-IgA1 levels, identifying elevated Gd-IgA1 as a heritable risk factor that preceded the development of IgAN.

"Very little is known about the causes of IgAN, genetic or otherwise, so our discovery represents an important step toward developing better therapies for this disease," said first author Dr. Krzysztof Kiryluk, assistant professor of medicine at Columbia University Medical Center. "Since approximately 50% of variability in Gd-IgA1 levels is due to genetic factors, this means that about 43% of the genetic variability is still unexplained. We started with a relatively small study population, so explaining 7% of variability between individuals with the disease was a good start. As we analyze more patients, we expect that we will find more genetic variants and can begin to piece together how these variants interact with environmental factors to cause disease."

The study was published in the February 10, 2017, online edition of the journal PLOS Genetics.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.